GGrantIndex
← Leaderboards

Ernesta Maria Meintjes

Massachusetts General Hospital

Google Scholar ↗PubMed ↗ORCID ↗
$4,925,944
Attributed
$15,809,828
Total exposure
10
Grants
1
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2.4M · FY2008–25
$2.5M$1.9M$1.3M$625K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$15,809,828 · 10

By mechanism

R01$14,485,912 · 6
R21$1,323,916 · 4

Top collaborators

Most similar at Massachusetts General Hospital

Same institution · by research overlap

Others in their field

Top investigators on “South Africa”

Research focus

South AfricaBrainUniversitiesChildBirthNeuroimagingMassachusettsMagnetic Resonance ImagingGeneral HospitalsCollaborationsBrain ImagingGrowthCommunitiesImageChildhoodMorphometryCohortNeurodevelopmentDiffusionStructureCognitiveInfantPregnant WomenSpectrum Analysis

Grant awards (37)

Fetal Neuroprotection by choline supplementation in heavy drinking pregnant women$262,442
R01 · FY2025 · AA
Neural correlates of in utero HIV and ART exposure: early childhood follow-up of a prospectively recruited cohort$249,545
R01 · FY2025 · HD
Neural correlates of in utero HIV and ART exposure: early childhood follow-up of a prospectively recruited cohort$209,938
R01 · FY2025 · HD
Fetal Neuroprotection by choline supplementation in heavy drinking pregnant women$209,677
R01 · FY2025 · AA
Neural correlates of in utero HIV and ART exposure: early childhood follow-up of a prospectively recruited cohort$117,578
R01 · FY2025 · HD
Neural correlates of in utero HIV and ART exposure: early childhood follow-up of a prospectively recruited cohort$590,497
R01 · FY2024 · HD
A Randomized, Double-Blind, Placebo-controlled Clinical Trial of Choline Supplementation during Pregnancy to Mitigate Adverse Effects of Prenatal Alcohol Exposure on Growth and Cognitive Development$572,927
R01 · FY2024 · AA
Fetal Neuroprotection by choline supplementation in heavy drinking pregnant women$447,811
R01 · FY2024 · AA
A Randomized, Double-Blind, Placebo-controlled Clinical Trial of Choline Supplementation during Pregnancy to Mitigate Adverse Effects of Prenatal Alcohol Exposure on Growth and Cognitive Development$730,105
R01 · FY2023 · AA
Neural correlates of in utero HIV and ART exposure: early childhood follow-up of a prospectively recruited cohort$652,205
R01 · FY2023 · HD
Extension of a longitudinal cognitive and brain imaging study of early-treated perinatally HIV infected children through adolescence$491,737
R01 · FY2023 · HD
Fetal Neuroprotection by choline supplementation in heavy drinking pregnant women$489,045
R01 · FY2023 · AA
A Randomized, Double-Blind, Placebo-controlled Clinical Trial of Choline Supplementation during Pregnancy to Mitigate Adverse Effects of Prenatal Alcohol Exposure on Growth and Cognitive Development$812,833
R01 · FY2022 · AA
Extension of a longitudinal cognitive and brain imaging study of early-treated perinatally HIV infected children through adolescence$490,028
R01 · FY2022 · HD
A Randomized, Double-Blind, Placebo-controlled Clinical Trial of Choline Supplementation during Pregnancy to Mitigate Adverse Effects of Prenatal Alcohol Exposure on Growth and Cognitive Development$864,859
R01 · FY2021 · AA
Extension of a longitudinal cognitive and brain imaging study of early-treated perinatally HIV infected children through adolescence$518,624
R01 · FY2021 · HD
A Randomized, Double-Blind, Placebo-controlled Clinical Trial of Choline Supplementation during Pregnancy to Mitigate Adverse Effects of Prenatal Alcohol Exposure on Growth and Cognitive Development$842,040
R01 · FY2020 · AA
Extension of a longitudinal cognitive and brain imaging study of early-treated perinatally HIV infected children through adolescence$566,542
R01 · FY2020 · HD
Neonatal imaging as an early marker of neurodevelopment and predictor of cognitive performance in infants exposed to HIV and ART in utero and perinatally$450,991
R01 · FY2020 · HD
Extension of a longitudinal cognitive and brain imaging study of early-treated perinatally HIV infected children through adolescence$632,178
R01 · FY2019 · HD
Neonatal imaging as an early marker of neurodevelopment and predictor of cognitive performance in infants exposed to HIV and ART in utero and perinatally$435,700
R01 · FY2019 · HD
Neonatal imaging as an early marker of neurodevelopment and predictor of cognitive performance in infants exposed to HIV and ART in utero and perinatally$456,404
R01 · FY2018 · HD
Neonatal imaging as an early marker of neurodevelopment and predictor of cognitive performance in infants exposed to HIV and ART in utero and perinatally$462,854
R01 · FY2017 · HD
Neonatal imaging as an early marker of neurodevelopment and predictor of cognitive performance in infants exposed to HIV and ART in utero and perinatally$537,079
R01 · FY2016 · HD
Longitudinal, multimodal analysis of HIV and ART effects on brain metabolism, structure and connectivity in young children$148,139
R21 · FY2016 · MH · contact PI
Longitudinal Neuroimaging and Cognitive Study of HIV-Infected Children$456,000
R01 · FY2015 · HD
Longitudinal, multimodal analysis of HIV and ART effects on brain metabolism, structure and connectivity in young children$149,599
R21 · FY2015 · MH · contact PI
Longitudinal Neuroimaging and Cognitive Study of HIV-Infected Children$449,942
R01 · FY2014 · HD
Longitudinal Neuroimaging and Cognitive Study of HIV-Infected Children$437,788
R01 · FY2013 · HD
Longitudinal Neuroimaging and Cognitive Study of HIV-Infected Children$498,642
R01 · FY2012 · HD
Brain Imaging of Newborns with Fetal Alcohol Syndrome$242,500
R21 · FY2012 · AA
Technology development and neuroimaging for 5 year old children with HIV infectio$124,625
R21 · FY2012 · MH
Longitudinal Neuroimaging and Cognitive Study of HIV-Infected Children$549,901
R01 · FY2011 · HD
Brain Imaging of Newborns with Fetal Alcohol Syndrome$242,540
R21 · FY2011 · AA
Technology development and neuroimaging for 5 year old children with HIV infectio$162,376
R21 · FY2011 · MH
Neuroimaging Technology for Pediatric Development Disorders in South Africa$117,630
R21 · FY2009 · AA
Neuroimaging Technology for Pediatric Development Disorders in South Africa$136,507
R21 · FY2008 · AA